Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ADA | P00813 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5322260 | 0.91 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1TDP1MTNR1A | |
| SCHEMBL5325351 | 0.89 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1TDP1MTNR1A | |
| SCHEMBL22394072 | 0.86 | MTNR1A (0.51) | SLC1A3SLC1A2SLC1A1TDP1MTNR1A | |
| SCHEMBL27254773 | 0.83 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1MTNR1A | |
| SCHEMBL660499 | 0.83 | CTNNB1 (0.59) | SLC1A3SLC1A2SLC1A1TDP1CTNNB1 | |
| SCHEMBL93516 | 0.83 | CTNNB1 (0.59) | SLC1A3SLC1A2SLC1A1TDP1CTNNB1 | |
| SCHEMBL29397858 | 0.83 | CTNNB1 (0.59) | SLC1A3SLC1A2SLC1A1TDP1CTNNB1 | |
| SCHEMBL29397866 | 0.83 | CTNNB1 (0.59) | SLC1A3SLC1A2SLC1A1TDP1CTNNB1 | |
| SCHEMBL29482763 | 0.83 | CTNNB1 (0.59) | SLC1A3SLC1A2SLC1A1TDP1CTNNB1 | |
| SCHEMBL8890206 | 0.83 | TDP1 (0.56) | SLC1A3SLC1A2SLC1A1TDP1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020023502-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | SLC1A3 4472/4885SLC1A2 4787/4885SLC1A1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.